MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$578,503
(51.67%↑ Y/Y)
Loss before income
taxes
-$578,503
(51.67%↑ Y/Y)
Loss from operations
-$386,529
(52.19%↑ Y/Y)
Total other expense
-$191,974
(50.58%↑ Y/Y)
Total operating
expenses
$386,529
(-52.19%↓ Y/Y)
Interest expense -
original issuance costs
$119,739
(20.79%↑ Y/Y)
Interest expense - debt
discount
$70,211
(-73.38%↓ Y/Y)
Interest expense
$2,024
(138.12%↑ Y/Y)
General and
administrative
$306,796
(-45.67%↓ Y/Y)
Stock based
compensation
$50,000
(33.33%↑ Y/Y)
Research and development
$29,681
(-85.60%↓ Y/Y)
Marketing expenses
$52
(-54.39%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)